Horizon Therapeutics (HZNP) option IV into confirms in deal discussions

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. IRT
7. QCOM
8. ASO
9. LAES
10. NTHI

Go back to Horizon Therapeutics (HZNP) option IV into confirms in deal discussions

Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case

December 1, 2022 11:06 AM EST

Jefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.

Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.

The analyst said the... More

'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks

November 30, 2022 10:39 AM EST

Shares of Viridian Therapeutics (NASDAQ: VRDN) jumped Wednesday on the back of news on Tuesday evening that Horizon Therapeutics (NASDAQ: HZNP) is in "highly preliminary discussions" with three large pharmaceutical companies.

Horizon Therapeutics shares are up more than 27% during Wednesday's session, while Viridian Therapeutics has also reacted to the news, currently up over 13%.

Within Horizon's portfolio of... More

Horizon Therapeutics seen worth up to $140/share in takeover

November 30, 2022 8:12 AM EST

Several Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.

Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More